TMFEBCapital

Todd Campbell

TMFEBCapital’s Activity

Thu Sep 22

NL

Article

EBCapitalMarkets published an article 4:40 PM

A Critical Couple of Months for Acadia Pharmaceuticals

The launch of its Parkinson's disease psychosis drug is in its early stages, and key data from an Alzheimer's disease trial is on tap.

NL

Article

EBCapitalMarkets published an article 3:40 PM

How Much Could DepoMed Fetch in a Deal?

DepoMed's board of directors may be willing to discuss selling the company.

Tue Sep 20

NL

Article

EBCapitalMarkets published an article 3:29 PM

3 Clinical-Stage Biotechs to Buy Ahead of FDA Decisions

Aerie Pharmaceuticals, Flexion Therapeutics, and Puma Biotechnology may have more running room ahead if regulators give their drugs the go-ahead.

NL

Article

EBCapitalMarkets published an article 11:48 AM

What's Behind Aerie Pharmaceuticals' 12.9% Rally Today

Shares are spiking after Wall Street analysts issue "buy" ratings.

NL

Article

EBCapitalMarkets published an article 11:18 AM

Forget Sarepta Therapeutics, Here Are 3 Other Biotech Stocks to Buy

Upcoming FDA decisions could lead to Portola Pharmaceuticals, Puma Biotech, and Tesaro Inc. outperforming Sarepta Therapeutics.

Mon Sep 19

NL

Article

EBCapitalMarkets published an article 5:31 PM

Why PTC Therapeutics Shares Skyrocketed 20.6% Today

The approval of Sarepta Therapeutics' eteplirsen is boosting optimism that the FDA will review PTC Therapeutics Translarna.

NL

Article

EBCapitalMarkets published an article 4:49 PM

Why Sarepta Therapeutics Soared 74% Today

The FDA has officially approved Exondys 51, a novel therapy for use in Duchenne muscular dystrophy.

NL

Article

EBCapitalMarkets published an article 1:50 PM

3 Index Funds to Buy in September

Buying these index funds this month could prove to be profit-friendly.

Sun Sep 18

NL

Article

EBCapitalMarkets published an article 12:02 PM

Middle America: Is a Trust Right for You?

Trusts can offer flexibility to everyday families, allowing grandparents and parents to have control over how their estate is to be distributed to beneficiaries.

Sat Sep 17

NL

Article

EBCapitalMarkets published an article 4:01 PM

Is Credit Putting Millennials on a Collision Course?

Millennials' reliance on credit cards could be putting a dent in their retirement savings plans.

NL

Article

EBCapitalMarkets published an article 11:41 AM

Is This New Market the Biggest Investment Idea of the Decade?

The market for biosimilar medicine could skyrocket to $20 billion in the coming years.

Fri Sep 16

NL

Article

EBCapitalMarkets published an article 3:54 PM

Why Aerie Pharmaceuticals Shares Are Rallying Another 11.9% Today

Enthusiasm over yesterday's Roclatan phase 3 results is trumping news of an equity offering today.

NL

Article

EBCapitalMarkets published an article 11:58 AM

Why DepoMed's Shares Are Jumping 12% Today

DepoMed's board of directors may be willing to discuss selling the company.

Thu Sep 15

NL

Article

EBCapitalMarkets published an article 1:05 PM

Why Aerie Pharmaceuticals Is Soaring 54% Today

Aerie Pharmaceuticals reported positive late-stage trial results from a key study evaluating Roclatan, a glaucoma therapy.

Wed Sep 14

NL

Article

EBCapitalMarkets published an article 4:43 PM

5 Tips for Avoiding Common Medicare Missteps

Medicare can be complicated, and if you don't understand its rules, you can end up getting short-changed.

NL

Article

EBCapitalMarkets published an article 3:22 PM

Does This News Make Sarepta Therapeutics a Buy?

Chances for approval of its lead drug candidate may have just improved following the departure of a big critic at the FDA.

NL

Article

EBCapitalMarkets published an article 11:58 AM

Why Sarepta Therapeutics' Shares Are Skyrocketing 25% Today

The departure of a critic of its Duchenne muscular dystrophy drug from the FDA is sparking optimism that an approval may be forthcoming.

Tue Sep 13

NL

Article

EBCapitalMarkets published an article 3:01 PM

3 Dividend Stocks to Buy in a Market Crash

International Business Machines, Pfizer, and ExxonMobil offer catalysts for growth, reasonable valuations, and stable dividend payments.

NL

Article

EBCapitalMarkets published an article 1:21 PM

Why Diplomat Pharmacy, Inc. Shares Tumbled 12.9% in August

Second-quarter financial results failed to impress investors.

NL

Article

EBCapitalMarkets published an article 11:13 AM

Is This Lexicon Pharmaceuticals' Year?

A pending FDA decision date and promising late-stage data could make 2016 a big year for this clinical-stage company.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 32.65
Player Rank 50427 out of 74869
Score -77.24
Score Change Today +23.93
Accuracy 36.11%
Active Picks 36
Total Picks 36
Best Pick MDVN (+145.61)
Worst Pick WFM (-75.40)
Average Score per Pick -2.15
Charms Earned 6
Highest Rated Favorite No Favorites Selected
Go to TMFEBCapital’s CAPS page

Boards Stats & Trivia

Board Posts 0
Recs Received 0
People who have rec'd these posts 0
Recs to Posts Ratio (last 30 days) N/A
Threads Started 0
Threads Started Percentage 0.00 %
Most Frequent Board N/A
Very First Post N/A
Percentage of Posts Rec'd 100.00 %
Show TMFEBCapital’s 10 Latest Posts